Abstract: The present invention is to simulate building of a ship at a detailed operation level by executing: a product model creating step S1 of creating a product model by obtaining basic design information 1 in which a coupling relation between a completed part and a component part of the ship is clarified; a facility model creating step S2 of obtaining equipment information 21 and worker information 22 of a factory and creating a facility model; a process model creating step S3 of clarifying assembling procedure and tasks to build the completed part and creating a process model based on the product model and the facility model; a simulation step S4 to carry out time evolution system simulation based on the process model; and a time series informatization step S5 of time series digitizing a result of the time evolution system simulation into building time series information 42.

Abstract: The present disclosure provides an adsorbent which is produced using a low environmental load material as a raw material and adsorbs selenious acid selectively and efficiently. A selenious acid adsorbent according to the present disclosure includes a cellulose derivative (I) having a repeating unit represented by Formula (I).

Abstract: The present disclosure provides a cellulose derivative which has excellent storage stability and can selectively adsorb a valuable metal and a toxic metal. The cellulose derivative of the present disclosure has a repeating unit represented by Formula (I) below. In Formula (I) below. Ras are identical or different and are a hydrogen atom or a group represented by Formula (a) below. In Formula (a) below, ring Z represents a heterocycle containing a nitrogen atom as a heteroatom, and R1 represents a single bond or an alkylene group having from 1 to 10 carbons. Four R2s are identical or different, and each represent an alkyl group having from 1 to 10 carbons. At least one of all the Ras included in the cellulose derivative is a group represented by Formula (a) below.

Abstract: The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-? production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof.

Abstract: The present invention has an object to provide a virtual reality video reproduction apparatus that can allow a viewer to experience an impairment due to a disease, such as diabetes, with a strong sense of immersion. The virtual reality video reproduction apparatus of the present invention applies a filter process of simulating a visual impairment caused by diabetes to a predetermined area of images included in a virtual reality video that represents virtual reality content, and causes an electronic display included in a virtual reality headset to display the video.

Abstract: The present invention has an object to provide a virtual reality video reproduction apparatus that can allow a viewer to experience an impairment due to a disease, such as diabetes, with a strong sense of immersion. The virtual reality video reproduction apparatus of the present invention applies a filter process of simulating a visual impairment caused by diabetes to a predetermined area of images included in a virtual reality video that represents virtual reality content, and causes an electronic display included in a virtual reality headset to display the video.

Abstract: The present invention has an object to provide a virtual reality video reproduction apparatus that can allow a viewer to experience an impairment due to a disease, such as diabetes, with a strong sense of immersion. The virtual reality video reproduction apparatus of the present invention applies a filter process of simulating a visual impairment caused by diabetes to a predetermined area of images included in a virtual reality video that represents virtual reality content, and causes an electronic display included in a virtual reality headset to display the video.

Abstract: The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the ?-chain region of the T cell receptor gene rearranged to uniform V?-J? in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the ?-chain region of a T cell receptor (TCR) gene has been rearranged to uniform V?-J?. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.

Abstract: The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-? production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof.

Abstract: The invention provides a compound effective as an antitumor active agent or vaccine adjuvant and an intermediate useful for the synthesis of the compound, as well as production methods thereof, and a medicament containing the novel compound. The compound is a carbamate glycolipid represented by the formula (I) wherein each symbol is as defined herein. The invention also provides a dendritic cell pulsed with the glycolipid.

Abstract: The invention provides a compound represented by the formula (I) wherein R1 is a hydrogen atom or a hydroxyl group; two R2 are the same or different and each is a hydrogen atom or a hydroxyl group; R3 is a hydrocarbon group having 8-14 carbon atoms, which optionally has substituent(s); and R4 is a hydrocarbon group having 18-24 carbon atoms, which optionally has substituent(s), or a salt thereof. The invention also provides a method of treating an autoimmune disease or suppressing immunity by administering the aforementioned compound or a salt thereof to a patient in need thereof.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Abstract: To provide a method of efficiently delivering cells having an anti-tumor activity to tumor tissues to evoke a stronger anti-tumor reaction, and a method of providing a more effective tumor regression effect, both in a cellular immunotherapy for cancer utilizing cells having an anti-tumor activity or antigen presenting cells for activating cells capable of exhibiting an anti-tumor activity. Provided are: a method of treating head and neck cancer, comprising administering an anti-cancer cell composition containing NKT cells activated in vitro with an NKT cell ligand into the tumor-feeding artery, and administering an NKT cell-stimulating agent containing antigen presenting cells treated with an NKT cell ligand through the upper respiratory tract mucous membrane; a use, in anti-cancer treatment of head and neck region, of the anti-cancer cell composition and the NKT cell-stimulating agent; a kit comprising the anti-cancer cell composition and the NKT cell-stimulating agent; and the anti-cancer cell composition.

Abstract: The invention provides a compound represented by the formula (I) wherein R1 is a hydrogen atom or a hydroxyl group; two R2 are the same or different and each is a hydrogen atom or a hydroxyl group; R3 is a hydrocarbon group having 8-14 carbon atoms, which optionally has substituent(s); and R4 is a hydrocarbon group having 18-24 carbon atoms, which optionally has substituent(s), or a salt thereof. The invention also provides a method of treating an autoimmune disease or suppressing immunity by administering the aforementioned compound or a salt thereof to a patient in need thereof.

Abstract: The invention provides a compound effective as an antitumor active agent or vaccine adjuvant and an intermediate useful for the synthesis of the compound, as well as production methods thereof, and a medicament containing the novel compound. The compound is a carbamate glycolipid represented by the formula (I) wherein each symbol is as defined herein. The invention also provides a dendritic cell pulsed with the glycolipid.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Abstract: Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the ?-chain region of the T cell antigen receptor gene rearranged to uniform V?-J? in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Abstract: A compound represented by the following formula (1): wherein R1 is an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, R2 is a C1-26 hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom or a C1-26 hydrocarbon group optionally having substituent(s), R4 is a C1-21 hydrocarbon group optionally having substituent(s), X is an oxygen atom or —CH2—, and Y is —CH2—, —CH(OH)— or —CH?CH—, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-? of NKT cells.

Abstract: The invention provides esterified ?-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein R1 is a hydrocarbon group having a carbon number of 1 to 30, R2 is a hydrocarbon group having a carbon number of 1 to 20, R3 is a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, R4 and R5 are the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or R4 and R5 in combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.